Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms 703Carcinoma, Renal Cell 231Urinary Bladder Neoplasms 202Carcinoma, Transitional Cell 117Breast Neoplasms 99Kidney Neoplasms 92Neoplasms 84Carcinoma, Non-Small-Cell Lung 83Ovarian Neoplasms 80Melanoma 80Colorectal Neoplasms 72Neoplasm Metastasis 68Non-Muscle Invasive Bladder Neoplasms 58Lung Neoplasms 56Pancreatic Neoplasms 48Sarcoma 45Endometrial Neoplasms 43Stomach Neoplasms 42Uterine Cervical Neoplasms 40Carcinoma, Hepatocellular 34Adenocarcinoma 34Wilms Tumor 33Esophageal Neoplasms 31Squamous Cell Carcinoma of Head and Neck 30Triple Negative Breast Neoplasms 29Head and Neck Neoplasms 29Metastatic Castration-resistant Prostate Cancer 25Testicular Neoplasms 24Neuroblastoma 23Colonic Neoplasms 23

Interventions

apalutamide 1Androgen Antagonists 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Metastatic Castrate-sensitive Prostate Cancer × Genitourinary × 90 days × Clear all
NCT05884398 2026-06-05

LIBERTAS

Janssen Research & Development, LLC

Phase 3 Active not recruiting
420 enrolled
Genitourinary

Metastatic Castrate-sensitive Prostate Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡